The acquisition is part of an effort to strengthen Allergan’s skin care division, according to the report.
The purchasing price values Vitae at $21 a share, compared with the company’s closing price of $8.10 per share on Tuesday, according to the report. Shares of Vitae spiked to $20.93 in premarket trading Wednesday, and Allergan shares rose 0.8 percent.
Under the deal, Allergan will acquire a drug currently in mid-stage trials that is designed to treat psoriasis, a disease that causes itchy dry skin patches, and other autoimmune disorders, according to the report.
More articles on supply chain:
Market exclusivity main factor in high drug prices, study finds
How can the Internet of (very valuable) things reduce costs in healthcare?
US faces shipping container shortage following Hanjin bankruptcy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
